Correction: Real-World Response and Super-Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study (Neurology and Therapy, (2026), 10.1007/s40120-026-00971-7)

In this article the first paragraph under section Exploratory Endpoints was incorrect as, Among dose-escalated patients, the ≥ 50%, ≥ 75%, and 100% response rates varied according to the number of 300 mg doses received, with patients receiving a single 300 mg dose having response rates at 48 weeks of 86.9%, 30.4%, and 0%, respectively, with no significant difference compared with those consistently treated with the 100 mg dose. In patients receiving two 300 mg doses, the ≥ 50%, ≥ 75%, and 100% response rates were 73.5%, 38.2%, and 8.8%, respectively, which were significantly lower than the corresponding rates in the consistently 100 mg-treated group (p = 0.005). Patients receiving three 300 mg doses had ≥ 50%, ≥ 75%, and 100% response rates of 82.8%, 58.6%, and 6.9%, respectively, again showing no significant difference compared with patients consistently treated with the 100 mg dose (Fig. 6). and should have read, Among dose-escalated patients, the ≥ 50%, ≥ 75%, and 100% response rates varied according to the number of 300 mg doses received (Fig. 6). For the ≥ 50% response threshold, responder proportions were similar between patients maintained on 100 mg and those who had received one, two, or three 300 mg doses. For the ≥ 75% threshold, the highest proportion was observed in patients maintained at 100 mg (71.1%), whereas lower proportions were observed in patients who had received one 300 mg dose (30.4%, p = 0.028) and two 300 mg doses (38.2%, p = 0.031). Patients who had received three 300 mg doses showed a non-statistically significant proportion (Fig. 6). In this article Figs. 8, 9 and 10 appeared incorrectly and have now been corrected in the original publication. For completeness and transparency, the incorrect and the correct versions are displayed below. Fig. 8 Responder rates at week 48 in patients without adverse events. Bars represent the proportion of patients achieving ≥ 50%, ≥ 75%, and 100% reduction in monthly migraine/headache days (MMD/MHD) relative to baseline among those reporting no adverse events. Data are shown for the total population (All, n = 117) and stratified by diagnosis: high-frequency episodic migraine (HFEM, n = 19) and chronic migraine (CM, n = 98). Chi-square analysis reveals a significant difference between the HFEM and CM groups, specifically within the ≥ 50% responder category (p = 0.049); no significant differences were observed in the other categories Responder rates at week 48 in patients without adverse events. Bars represent the proportion of patients achieving ≥ 50%, ≥ 75%, and 100% reduction in monthly migraine/headache days (MMD/MHD) relative to baseline among those reporting no adverse events. Data are shown for the total population (All, n = 117) and stratified by diagnosis: high-frequency episodic migraine (HFEM, n = 19) and chronic migraine (CM, n = 98). Chi-square analysis reveals a significant difference between the HFEM and CM groups, specifically within the ≥ 50% responder category (p = 0.049); no significant differences were observed in the other categories Fig. 9 Proportion of responders achieving ≥ 30% reduction in numerical rating scale (NRS) score during residual attacks at week 48. Bars represent the percentage of patients within the ≥ 50% and ≥ 75% responder categories who also experienced a significant reduction in pain intensity (NRS ≥ 30%) for remaining attacks. Data are presented for the total population (All, n = 124) and stratified by diagnosis: high-frequency episodic migraine (HFEM, n = 21) and chronic migraine (CM, n = 103). Chi-square analysis shows no significant differences between HFEM and CM groups for these combined outc